Eli Lilly vs Medtronic stock
Side by side in plain words: who keeps more of its sales, grows faster, costs less and owes less.
Eli Lilly is more profitable, grows faster and has less debt. Medtronic is cheaper for its profits.
Side by side
| Eli Lilly | Medtronic | |
|---|---|---|
| $1.20 trillion | $128 billion | |
| 31.7% | 13.2% | |
| +21.6% | +3.8% | |
| 58.1× | 26.6× | |
| 1.1 years | 2.7 years | |
| 34.8% | 7.2% | |
| 0.6% | 3.5% |
How we compare
Four contests with the same rules as each stock page: profit kept from sales (higher wins), yearly sales growth across the last reports, up to five years (higher wins), price per unit of yearly profit (lower P/E wins; a company without profit loses) and debt in years of earnings (lower wins). A winner is only named when both companies have the number.
More comparisons: Eli Lilly vs Merck & · Eli Lilly vs Merck KGaA · Eli Lilly vs Moderna · Eli Lilly vs Natera · Medtronic vs McKesson · Medtronic vs Novo Nordisk · Medtronic vs Regeneron Pharmaceuticals · Medtronic vs Roche

